In patients with VOD post-HSCT, what would be the role of TPO agonists instead of platelet transfusions, given their platelet refractoriness and concerns for fluid overload?  

This is an insightful question, as it addresses a key issue in the management of veno-occlusive disease (VOD) - chiefly, how does one minimize the amount of fluid being given, but at the same time, support patients with persistently low platelet counts, the majority of whom will be on a therapy whic...